Lv6
3146 积分 2022-05-02 加入
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial
1个月前
已关闭
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
1个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1个月前
已关闭
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
2个月前
已完结
Role of ivabradine in pediatrics: A review article
2个月前
已完结
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
2个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
3个月前
已完结
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
3个月前
已完结
皖公网安备34019202002308
